摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-t-butyl ester 2-ethyl ester | 937814-62-5

中文名称
——
中文别名
——
英文名称
(2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-t-butyl ester 2-ethyl ester
英文别名
(2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester;1-O-tert-butyl 2-O-ethyl (2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylate
(2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-t-butyl ester 2-ethyl ester化学式
CAS
937814-62-5
化学式
C18H24ClNO4
mdl
——
分子量
353.846
InChiKey
FYZXOKGDQKHWDD-LSDHHAIUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Prodrug of cinnamide compound
    申请人:Kimura Teiji
    公开号:US20090048213A1
    公开(公告)日:2009-02-19
    The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I) wherein R a and R b each denote a C1-6 alkyl group or the like; X a denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.
    本发明提供了一种桂皮酰胺化合物的最适宜的前药。该前药由式(I)表示,其中R a 和R b 分别表示C1-6烷基或类似物;X a 表示甲氧基或氟原子;Y表示磷酸酯基团或类似物;A表示环内酰胺衍生物。
  • Two cyclic cinnamide compound
    申请人:Kimura Teiji
    公开号:US20070117839A1
    公开(公告)日:2007-05-24
    The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.
    本发明涉及一种新型的二环丙烯酰胺化合物和包含该化合物作为活性成分的药物。所述二环丙烯酰胺化合物由通式(I)表示:其中,表示单键或双键;Ar1表示苯基或吡啶基,可以被1至3个取代基取代;R1和R2分别表示C1-6烷基、羟基或类似物;Z1表示亚甲基或乙烯基,可以被从取代基A1中选择的1或2个取代基、氧原子或取代基A1选择的亚胺基取代;p、q和r分别表示0至2的整数,具有降低Aβ40和Aβ42生成的作用,因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病,如阿尔茨海默病或唐氏综合症的药物。
  • BICYCLIC OXOMORPHOLINE DERIVATIVE
    申请人:Kimura Teiji
    公开号:US20100113773A1
    公开(公告)日:2010-05-06
    The present invention relates to a compound represented by formula (I): wherein R 1 represents a C1-3 alkyl group, R 2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
    本发明涉及一种由以下化学式(I)表示的化合物:其中,R1代表C1-3烷基;R2代表氢原子或C1-3烷基;Ar代表苯基或类似物,可以被1至3个取代基取代;X代表氧原子或类似物;n和m相同或不同,是0至2的整数;或其药学上可接受的盐,并将其用作药物。
  • Bicyclic oxomorpholine derivative
    申请人:Eisai R&D Management Co., Ltd.
    公开号:US08008293B2
    公开(公告)日:2011-08-30
    The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.
    本发明涉及一种化合物,其化学式表示为(I):其中R1代表C1-3烷基,R2代表氢原子或C1-3烷基,Ar代表苯基或类似物,可以被1至3个取代基取代,X代表氧原子或类似物,n和m相同或不同,都是0至2的整数,或其药学上可接受的盐,并将其用作药物。
  • TWO CYCLIC CINNAMIDE COMPOUND
    申请人:Kimura Teiji
    公开号:US20090181945A1
    公开(公告)日:2009-07-16
    The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.
    本发明涉及一种新型的双环肉桂酰胺化合物和一种以该化合物为活性成分的药物制剂。该双环肉桂酰胺化合物由通式(I)表示:其中,表示单键或双键;Ar1表示苯基或吡啶基,可以用1至3个取代基取代;R1和R2各表示C1-6烷基、羟基或类似物;Z1表示亚甲基或乙烯基,可以用来自取代基A1的1或2个取代基、氧原子或可用取代基A1取代的亚胺基取代;p、q和r各表示0至2的整数,具有减少Aβ40和Aβ42产生的作用,因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病,如阿尔茨海默病或唐氏综合症的药物制剂。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物